Henrik Zetterberg

Summary

Country: Sweden

Publications

  1. ncbi Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease
    Henrik Zetterberg
    Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at Goteborg University, Molndal, Sweden
    Arch Neurol 65:1102-7. 2008
  2. ncbi Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs
    Erik Portelius
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden
    J Alzheimers Dis 21:1005-12. 2010
  3. ncbi Cerebrospinal fluid biomarkers for Alzheimer's disease: more to come?
    Henrik Zetterberg
    Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at University of Gothenburg, Sweden
    J Alzheimers Dis 33:S361-9. 2013
  4. ncbi Clinical use of cerebrospinal fluid biomarkers in Alzheimer's disease
    Henrik Zetterberg
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, Molndal, Sweden
    Biomark Med 6:371-6. 2012
  5. ncbi Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
    Kaj Blennow
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, SE 431 80 Molndal, Sweden
    Alzheimers Res Ther 2:8. 2010
  6. ncbi Identification of a beta-amyloid-binding plasma protein, LRP1: implications for biomarker research and therapy in Alzheimer's disease
    Henrik Zetterberg
    Goteborg University, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, S 431 80 Molndal, Sweden
    Biomark Med 1:347-8. 2007
  7. ncbi Amyloid beta and APP as biomarkers for Alzheimer's disease
    Henrik Zetterberg
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, S 431 80 Molndal, Sweden
    Exp Gerontol 45:23-9. 2010
  8. ncbi Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients
    Henrik Zetterberg
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Molndal, Sweden
    Eur Neurol 63:326-30. 2010
  9. ncbi Biochemical markers in Alzheimer's disease clinical trials
    Henrik Zetterberg
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden
    Biomark Med 4:91-8. 2010
  10. ncbi Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease
    Henrik Zetterberg
    Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, S 431 80 Molndal, Sweden
    Alzheimers Res Ther 2:32. 2010

Detail Information

Publications136 found, 100 shown here

  1. ncbi Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease
    Henrik Zetterberg
    Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at Goteborg University, Molndal, Sweden
    Arch Neurol 65:1102-7. 2008
    ....
  2. ncbi Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs
    Erik Portelius
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden
    J Alzheimers Dis 21:1005-12. 2010
    ..The data presented suggests that the γ-secretase modulator E-2012 alters the cleavage site preference of γ-secretase. The increase in Aβ(1-37) may inhibit Aβ(1-42) oligomerization and toxicity...
  3. ncbi Cerebrospinal fluid biomarkers for Alzheimer's disease: more to come?
    Henrik Zetterberg
    Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at University of Gothenburg, Sweden
    J Alzheimers Dis 33:S361-9. 2013
    ....
  4. ncbi Clinical use of cerebrospinal fluid biomarkers in Alzheimer's disease
    Henrik Zetterberg
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, Molndal, Sweden
    Biomark Med 6:371-6. 2012
    ..Here, we discuss how they may be employed in the clinical evaluation of patients with memory problems. We argue for their proper application and use, and caution against common misinterpretations...
  5. ncbi Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
    Kaj Blennow
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, SE 431 80 Molndal, Sweden
    Alzheimers Res Ther 2:8. 2010
    ..More details are needed, however, on how these biomarkers can be standardized, to allow a general implementation in the clinical routine diagnostic work-up of patients with cognitive disturbances...
  6. ncbi Identification of a beta-amyloid-binding plasma protein, LRP1: implications for biomarker research and therapy in Alzheimer's disease
    Henrik Zetterberg
    Goteborg University, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, S 431 80 Molndal, Sweden
    Biomark Med 1:347-8. 2007
    ..Furthermore, it would be interesting to explore the possibility that reduced sLRP1 levels in plasma may be a specific biochemical sign of incipient AD...
  7. ncbi Amyloid beta and APP as biomarkers for Alzheimer's disease
    Henrik Zetterberg
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, S 431 80 Molndal, Sweden
    Exp Gerontol 45:23-9. 2010
    ..We also consider their usefulness in clinical practice and in clinical trials...
  8. ncbi Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients
    Henrik Zetterberg
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Molndal, Sweden
    Eur Neurol 63:326-30. 2010
    ..To examine the incidence of post-lumbar puncture headache (PLPH) in patients admitted for cognitive disturbances...
  9. ncbi Biochemical markers in Alzheimer's disease clinical trials
    Henrik Zetterberg
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden
    Biomark Med 4:91-8. 2010
    ....
  10. ncbi Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease
    Henrik Zetterberg
    Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, S 431 80 Molndal, Sweden
    Alzheimers Res Ther 2:32. 2010
    ..Such biomarkers may be called 'theragnostic'. Here, we review the literature addressing the prospective value of these biomarkers...
  11. ncbi Update on amyloid-beta homeostasis markers for sporadic Alzheimer's disease
    Henrik Zetterberg
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at Goteborg University, Molndal, Sweden
    Scand J Clin Lab Invest 69:18-21. 2009
    ..This update summarizes the currently available studies that have determined the usefulness of BACE1 and secreted fragments of APP and Abeta as cerebrospinal fluid biomarkers for AD...
  12. ncbi Sustained release of neuron-specific enolase to serum in amateur boxers
    Henrik Zetterberg
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden
    Brain Inj 23:723-6. 2009
    ..We assess the potential of a panel of serum biomarkers to identify chronic neuronal injury in amateur boxers as compared to healthy controls without any history of head trauma...
  13. ncbi Is plasma amyloid-beta a reliable biomarker for Alzheimer's disease?
    Henrik Zetterberg
    Institute of Neuroscience and Physiology, Department of Neurochemistry and Psychiatry, The Sahlgrenska Academy at Gothenburg University, Sahlgrenska University Hospital Molndal, S 431 80 Molndal, Sweden
    Recent Pat CNS Drug Discov 3:109-11. 2008
    ..This review provides an update on the current status of research on plasma Abeta as a biomarker for AD in the context of recent patents in the field...
  14. ncbi Association of the RAGE G82S polymorphism with Alzheimer's disease
    Jonny Daborg
    Department of Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, 432, 405 30, Gothenburg, Sweden
    J Neural Transm 117:861-7. 2010
    ..4), and none of the AGER SNPs showed association with Abeta(42), T-tau, P-tau(181) or mini-mental state examination scores. The data speak for a weak, but significant effect of AGER on risk of AD...
  15. ncbi Association of complement factor H Y402H gene polymorphism with Alzheimer's disease
    Madeleine Zetterberg
    Department of Clinical Neuroscience and Rehabilitation, Institute of Neuroscience and Physiology, Section of Ophthalmology, The Sahlgrenska Academy at Goteborg University, Molndal, Sweden
    Am J Med Genet B Neuropsychiatr Genet 147:720-6. 2008
    ..The CFH 1277C allele may predispose patients for co-morbidity in AD and AMD...
  16. ncbi Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract
    Malin von Otter
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Bla Straket 15, the Sahlgrenska Academy at University of Gothenburg, S 413 45 Gothenburg, Sweden
    Mech Ageing Dev 131:105-10. 2010
    ..009). Our findings do not support NFE2L2 or KEAP1 as susceptibility genes for AD or cataract. However, common variants of the NFE2L2 gene may affect disease progression, potentially altering clinically recognized disease onset...
  17. ncbi Variability in the kinesin light chain 1 gene may influence risk of age-related cataract
    Malin E Andersson
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    Mol Vis 13:993-6. 2007
    ..Here, we test the hypothesis that the rs8702 polymorphism in the kinesin light chain 1 gene (KLC1), previously linked to Alzheimer disease (AD), may play a role in cataractogenesis...
  18. ncbi Kinesin light chain 1 gene haplotypes in three conformational diseases
    Malin von Otter
    Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
    Neuromolecular Med 12:229-36. 2010
    ..Altogether, these results do not convincingly support KLC1 as a major susceptibility gene in any of the studied diseases, although there is a small effect of KLC1 in relation to cataract...
  19. ncbi Low cerebrospinal fluid sulfatide predicts progression of white matter lesions: The LADIS study
    Michael Jonsson
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Sweden
    Dement Geriatr Cogn Disord 34:61-7. 2012
    ..The neurochemistry of ongoing WML is only partially known. We explored cerebrospinal fluid (CSF) substances as markers of brain tissue damage in relation to progression of WML rated on magnetic resonance imaging...
  20. ncbi A novel ARC gene polymorphism is associated with reduced risk of Alzheimer's disease
    Sara Landgren
    Department of Pharmacology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
    J Neural Transm 119:833-42. 2012
    ..However, further investigation of the importance of this SNP for ARC function, ARC processing and the pathology of AD is needed...
  21. ncbi Leukocyte telomere length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's disease: a pilot study
    Sofia Movérare-Skrtic
    Institute of Medicine, Department of Internal Medicine, The Sahlgrenska Academy, University of Gothenburg, S 41345 Gothenburg, Sweden
    Exp Gerontol 47:179-82. 2012
    ..Patients with stable MCI that did not progress to dementia had reduced LTL compared to controls, which might suggest a more marked biological aging as a cause of the cognitive symptoms in this group...
  22. ncbi Reward-related genes and personality traits in alcohol-dependent individuals: a pilot case control study
    Sara Landgren
    Department of Pharmacology, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
    Neuropsychobiology 64:38-46. 2011
    ..In conclusion, this pilot study suggests that reward-related genes are associated with altered personality scores in type 1 alcohol dependence, which warrants future studies of these associations in larger study samples...
  23. ncbi Association of nAChR gene haplotypes with heavy alcohol use and body mass
    Sara Landgren
    Institute of Neuroscience and Physiology, Department of Pharmacology, University of Gothenburg, Sweden
    Brain Res 1305:S72-9. 2009
    ....
  24. ncbi Subcortical vascular dementia biomarker pattern in mild cognitive impairment
    Maria Bjerke
    Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden
    Dement Geriatr Cogn Disord 28:348-56. 2009
    ..Mild cognitive impairment (MCI) is an etiologically unclear disorder. Cerebrospinal fluid (CSF) biomarkers are potentially useful for the differentiation between various MCI etiologies...
  25. ncbi Genetic variation of the ghrelin signaling system in females with severe alcohol dependence
    Sara Landgren
    Department of Pharmacology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
    Alcohol Clin Exp Res 34:1519-24. 2010
    ....
  26. ncbi No association of VEGF polymorphims with Alzheimer's disease
    Sara Landgren
    Department of Pharmacology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Medicinaregatan 13A, Gothenburg, Sweden
    Neuromolecular Med 12:224-8. 2010
    ..No significant associations with risk for AD or any of the studied biomarkers could be found in this study, thus not supporting VEGF as being a major risk gene for AD...
  27. ncbi Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease
    Malin E Andersson
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    Int J Mol Med 20:233-9. 2007
    ..018). These findings support earlier indications that genetic variability in the KNS2 gene may play a role during early stages of AD pathogenesis...
  28. ncbi Extreme stability of chitotriosidase in cerebrospinal fluid makes it a suitable marker for microglial activation in clinical trials
    Bob Olsson
    Department of Psychiatry and Neurochemistry, University of Gothenburg, Molndal, Sweden
    J Alzheimers Dis 32:273-6. 2012
    ..Thus, chitotriosidase may be useful in clinical trials where microglia is targeted or as a safety biomarker in other trials where the brain is a bystander organ...
  29. ncbi CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment
    Niklas Mattsson
    Institute of Neuroscience and Physiology, Department of Neurochemistry and Psychiatry, the Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden
    JAMA 302:385-93. 2009
    ....
  30. ncbi Ubiquitin carboxyl-terminal esterase L1 (UCHL1) S18Y polymorphism in patients with cataracts
    Thiemo Rudolph
    Department of Clinical Neuroscience and Rehabilitation, Institute of Neuroscience and Physiology, Section of Ophthalmology, The Sahlgrenska Academy at the University of Gothenburg, Molndal, Sweden
    Ophthalmic Genet 32:75-9. 2011
    ..A protective role of the p.S18Y polymorphism of the UCHL1 gene has been shown in Parkinson`s disease. The current study aimed to examine possible effects on cataract formation...
  31. ncbi Converging pathways of chromogranin and amyloid metabolism in the brain
    Niklas Mattsson
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Gothenburg and Mölndal, Sweden
    J Alzheimers Dis 20:1039-49. 2010
    ..Cell medium from BACE1-inhibited cells had decreased CgB levels. These results suggest that a large part of AbetaPP in the human central nervous system is processed in the regulated secretory pathway of neurons...
  32. ncbi High education may offer protection against tauopathy in patients with mild cognitive impairment
    Sindre Rolstad
    Institute of Neuroscience and Physiology, Section for Neurochemistry and Psychiatry, The Sahlgrenska Academy at Goteborg University, Molndal, Sweden
    J Alzheimers Dis 21:221-8. 2010
    ..Also, educational level predicted a significant proportion of the total variance in t-tau concentrations. Our results suggest that higher education may offer protection against tauopathy...
  33. ncbi Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluid
    Erik Portelius
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, S 431 80 Molndal, Sweden
    Exp Neurol 223:351-8. 2010
    ....
  34. ncbi Characterization of tau in cerebrospinal fluid using mass spectrometry
    Erik Portelius
    Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, University of Goteborg, Sahlgrenska University Hospital, S 431 80 Molndal, Sweden
    J Proteome Res 7:2114-20. 2008
    ..Nineteen tryptic fragments of tau were detected, of which 16 are found in all tau isoforms while 3 represented unique tau isoforms. These results pave the way for clinical CSF studies on the tauopathies...
  35. ncbi Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease
    Maria Bjerke
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden
    J Alzheimers Dis 27:665-76. 2011
    ..The CSF biomarkers reflecting AD pathology (T-tau, P-tau(181), and Aβ(1-42)), white matter lesions (NF-L and MBP) and matrix remodeling (MMP-9 and TIMP-1) perform well in differentiating between SVD and AD patients...
  36. ncbi Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer's disease
    Jonny Daborg
    Department of Physiology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 405 30, Gothenburg, Sweden
    J Neural Transm 119:789-97. 2012
    ..These results provide support for aberrant complement regulation as a part in the AD process, but the changes are not diagnostically useful...
  37. ncbi Evaluation of the performance of novel Aβ isoforms as theragnostic markers in Alzheimer's disease: from the cell to the patient
    Erik Portelius
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Molndal, Sweden
    Neurodegener Dis 10:138-40. 2012
    ....
  38. ncbi Cerebrospinal fluid profiles of amyloid β-related biomarkers in Alzheimer's disease
    Christoffer Rosén
    Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Molndal, Sweden
    Neuromolecular Med 14:65-73. 2012
    ....
  39. ncbi Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, S 431 80 Molndal, Sweden
    Neuromolecular Med 13:151-9. 2011
    ..Microglial markers are unlikely to be useful for AD diagnosis, but might be useful for identification of distinct subgroups of patients, and for the development and implementation of drugs targeting microglial pathology...
  40. ncbi Apolipoprotein E polymorphisms in patients with primary open-angle glaucoma
    Madeleine Zetterberg
    Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation, Section of Ophthalmology, The Sahlgrenska Academy at Goteborg University, Molndal, Sweden
    Am J Ophthalmol 143:1059-60. 2007
    ..To investigate apolipoprotein E (APOE) polymorphisms, which are known to influence the risk of Alzheimer disease (AD), in patients with primary open-angle glaucoma (POAG)...
  41. ncbi Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients
    Sara F Hansson
    Neurochemical Laboratory, Department of Neuroscience and Physiology, Section of Psychiatry and Neurochemistry, The Sahlgrenska Academy at Goteborg University, Sahlgrenska University Hospital Molndal, Molndal, Sweden
    J Alzheimers Dis 16:389-97. 2009
    ..015). Positive correlations between Abeta(1-42) and beta-trace, CysC and TTR, respectively, were seen only in the AD group, suggesting that deficient Abeta-binding capacity in CSF may contribute to the amyloidogenic process in AD...
  42. ncbi Methylenetetrahydrofolate reductase genetic polymorphisms in patients with primary open-angle glaucoma
    Madeleine Zetterberg
    Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation, Section of Ophthalmology, The Sahlgrenska Academy at Goteborg University, Molndal, Sweden
    Ophthalmic Genet 28:47-50. 2007
    ..The purpose of the present study was to determine if hyperhomocysteinemia-associated polymorphisms of the methylenetetrahydrofolate reductase gene (MTHFR) are overrepresented in primary open-angle glaucoma...
  43. ncbi Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease
    Annika Thorsell
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden
    Brain Res 1362:13-22. 2010
    ..These results together suggest that cerebrospinal fluid neurogranin might be valuable together with the established AD biomarkers in the early diagnosis of AD and warrants further studies to determine the diagnostic value of neurogranin...
  44. ncbi Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Molndal, Sweden
    Biomark Med 6:401-7. 2012
    ..Global proficiency testing for CSF biomarkers is now fully established. It will continue to play an important part in the standardization of measurements that is a prerequisite for the broad-scale future implementation of CSF biomarkers...
  45. ncbi Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Molndal, Sweden
    Biomark Med 6:409-17. 2012
    ..We describe possible technical approaches, focusing on a selected reaction monitoring mass spectrometry assay as a candidate reference method for quantification of CSF amyloid β42...
  46. ncbi Proteomic profiling of cerebrospinal fluid in parkinsonian disorders
    Radu Constantinescu
    Institute of Neuroscience and Physiology, Department of Neurology, The Sahlgrenska Academy at the University of Gothenburg, 413 45 Goteborg, Sweden
    Parkinsonism Relat Disord 16:545-9. 2010
    ..However, they could not differentiate PD patients from controls. As none of these changes were APD subgroup-specific, they most likely reflect the intensity and/or extent of the neurodegenerative process in general...
  47. ncbi BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous system
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Molndal, Sweden
    PLoS ONE 7:e31084. 2012
    ..The described CSF Aβ pattern may be used as a pharmacodynamic fingerprint to detect biochemical effects of BACE1-therapies in clinical trials, which might accelerate development of novel therapies...
  48. ncbi No association of LOXL1 gene polymorphisms with Alzheimer's disease
    Alexandra Abramsson
    Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
    Neuromolecular Med 13:160-6. 2011
    ..No evidence for associations of these polymorphisms with risk for AD or any of the studied CSF biomarkers measured was found. These results do not support LOXL1 as being a major risk gene for AD...
  49. ncbi SILAC zebrafish for quantitative analysis of protein turnover and tissue regeneration
    Ann Westman-Brinkmalm
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Sweden
    J Proteomics 75:425-34. 2011
    ..This newly developed SILAC zebrafish model constitutes a novel tool to analyze tissue regeneration in an animal model amenable to genetic and pharmacologic manipulation...
  50. ncbi Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) S18Y polymorphism in Alzheimer's disease
    Madeleine Zetterberg
    Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation, Section of Ophthalmology, The Sahlgrenska Academy at the University of Gothenburg, Molndal, Sweden
    Mol Neurodegener 5:11. 2010
    ..82 ([95% CI 0.55-1.24], P = 0.35) was obtained for a positive UCHL1 allele A carrier status. The present study thus do not support a protective effect of the UCHL1 S18Y polymorphism against AD...
  51. ncbi Proteomics/peptidomics tools to find CSF biomarkers for neurodegenerative diseases
    Ann Westman-Brinkmalm
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neuochemistry, The Sahlgrenska Academy at Goteborg University, Sweden
    Front Biosci 14:1793-806. 2009
    ..In this review we discuss our experience in the field of neuroproteomics/peptidomics, with special focus on biomarker discovery studies that have been performed on CSF samples from well-defined patient and control populations...
  52. ncbi Effects of gamma-secretase inhibition on the amyloid beta isoform pattern in a mouse model of Alzheimer's disease
    Erik Portelius
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, SE 431 80 Molndal, Sweden
    Neurodegener Dis 6:258-62. 2009
    ..g. Abeta1-15 and Abeta1-16), and that the levels of these shorter isoforms are elevated in media from cells that have been treated with gamma-secretase inhibitors...
  53. ncbi Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
    Annika Ohrfelt
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden
    Neurosci Lett 450:332-5. 2009
    ..The lower alpha-syn levels in AD, as well as the association of alpha-syn reduction with AD severity, approximated by MMSE, suggests that it may be a general marker of synapse loss, a hypothesis that warrants further investigation...
  54. ncbi Converging molecular pathways in human neural development and degeneration
    Niklas Mattsson
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at University of Gothenburg, Göteborg Mölndal, Sweden
    Neurosci Res 66:330-2. 2010
    ..Tau phosphorylation in Alzheimer's disease may be a physiological response to Alzheimer-associated synaptotoxicity...
  55. ncbi Longitudinal stability of CSF biomarkers in Alzheimer's disease
    Kaj Blennow
    Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Molndal, Sweden
    Neurosci Lett 419:18-22. 2007
    ....
  56. ncbi Amyloid-β metabolism in Niemann-Pick C disease models and patients
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Molndal, Gothenburg, Sweden
    Metab Brain Dis 27:573-85. 2012
    ..The preliminary findings from NPC cats suggest that treatment with cyclodextrin may have an impact on APP processing pathways. CSF Aβ, sAPP and tau biomarkers were dynamically altered over time in human NPC patients...
  57. ncbi Analytical aspects of molecular Alzheimer's disease biomarkers
    Ulf Andreasson
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Molndal, Sweden
    Biomark Med 6:377-89. 2012
    ..In the field of Alzheimer's disease, there are currently three cerebrospinal fluid markers that have been verified in multiple studies and the analytical aspects of measuring them will be discussed...
  58. ncbi Neurochemical measures co-vary with personality traits: forensic psychiatric findings replicated in a general population sample
    Thomas Nilsson
    Institute of Neuroscience and Physiology, University of Gothenburg, Sweden
    Psychiatry Res 178:525-30. 2010
    ....
  59. ncbi An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid β and amyloid precursor protein in human and cat cerebrospinal fluid
    Gunnar Brinkmalm
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden
    J Mass Spectrom 47:591-603. 2012
    ..We here describe a detailed characterization of endogenous APP/Aβ peptide species in CSF by using an online top-down MS-based method...
  60. ncbi Identification of novel α-synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method
    Annika Ohrfelt
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, S 43180 Mölndal, Sweden
    Neurochem Res 36:2029-42. 2011
    ..Quantification of α-syn in each brain tissue fraction was performed using a novel enzyme-linked immunosorbent assay (ELISA)...
  61. ncbi Identification of novel APP/Abeta isoforms in human cerebrospinal fluid
    Erik Portelius
    Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, University of Goteborg, Sahlgrenska University Hospital, Molndal, Sweden
    Neurodegener Dis 6:87-94. 2009
    ..A lot of research has focused on Abeta production and the neurotoxic 42-amino-acid form of Abeta (Abeta1-42), while less is known about the nonamyloidogenic pathway and how Abeta is degraded...
  62. ncbi Amyloid-β₄₂ is associated with cognitive impairment in healthy elderly and subjective cognitive impairment
    Sindre Rolstad
    Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Molndal, Sweden
    J Alzheimers Dis 26:135-42. 2011
    ..Aβ₄₂ is associated with cognitive functions from a potentially early to a later disease phase, and T-tau is more indicative of performance in a later disease phase...
  63. ncbi A novel pathway for amyloid precursor protein processing
    Erik Portelius
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, S 431 80 Molndal, Sweden
    Neurobiol Aging 32:1090-8. 2011
    ....
  64. ncbi Is there a CSF biomarker profile related to depression in elderly women?
    Pia Gudmundsson
    Institute of Neuroscience and Physiology, Section for Psychiatry and Neurochemistry, Sahlgrenska Academy at University of Gothenburg, Sweden
    Psychiatry Res 176:174-8. 2010
    ..This contrasts with the well-characterized pattern of low Abeta42, higher CSF/serum albumin ratio, and higher NFL in Alzheimer's disease...
  65. ncbi Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease
    Erik Portelius
    Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Molndal, Sweden
    Acta Neuropathol 120:185-93. 2010
    ..No prominent differences in Abeta isoform patterns between FAD and SAD patients were seen, underscoring the similarity in the amyloid pathology of these two disease entities...
  66. ncbi Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women
    Deborah R Gustafson
    The Institute of Neuroscience and Physiology, Section for Psychiatry and Neurochemistry, Neuropsychiatric Epidemiology Unit, Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    J Neurol Neurosurg Psychiatry 78:461-4. 2007
    ..It is not known, however, whether these biomarkers may be risk indicators for cognitive decline in otherwise healthy older people...
  67. ncbi Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis
    Niklas Mattsson
    Department of Neurochemistry and Psychiatry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at Goteborg University, Molndal, Sweden
    J Neurochem 103:1932-9. 2007
    ..Further studies will investigate the involvement of these peptides in MS pathogenesis...
  68. ncbi Mass spectrometric characterization of amyloid-β species in the 7PA2 cell model of Alzheimer's disease
    Erik Portelius
    Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Molndal, Sweden
    J Alzheimers Dis 33:85-93. 2013
    ..The formation of these AβPP/Aβ peptides may have implications for the use of the 7PA2 cell line as a model for Aβ pathology. The enzyme(s) responsible for this particular BACE1-independent AβPP-processing remains to be identified...
  69. ncbi Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Molndal, Sweden
    J Alzheimers Dis 30:767-78. 2012
    ..Knowledge on these biomarkers and their trajectories may facilitate early diagnosis of AD and be useful in future clinical trials to track effects of disease modifying drugs...
  70. ncbi Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry
    Erik Portelius
    Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, University of Goteborg, Sahlgrenska University Hospital, S 431 80 Molndal, Sweden
    J Proteome Res 6:4433-9. 2007
    ..Finally, we report the finding of two novel Abeta peptides (Abeta2-17 and Abeta3-17)...
  71. ncbi An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid
    Erik Portelius
    Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, University of Goteborg, Sahlgrenska University Hospital, Molndal, Sweden
    Neurosci Lett 409:215-9. 2006
    ..Here, we provide direct evidence that an Abeta fragment signature consisting of Abeta1-16, Abeta1-33, Abeta1-39, and Abeta1-42 in CSF distinguishes sporadic AD patients from non-demented controls with an overall accuracy of 86%...
  72. ncbi Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Molndal, Sweden
    BMC Neurol 10:51. 2010
    ..We have previously found altered cerebral amyloid metabolism in other neuroinflammatory conditions. To further elucidate this, we investigated amyloid metabolism in patients with Lyme neuroborreliosis (LNB)...
  73. ncbi The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Molndal, Sweden
    Alzheimers Dement 7:386-395.e6. 2011
    ..In this article, we present the results from the first two rounds of the program...
  74. ncbi The N-terminal domain of α-dystroglycan, released as a 38 kDa protein, is increased in cerebrospinal fluid in patients with Lyme neuroborreliosis
    Camilla Hesse
    Institute of Biomedicine, Department of Clinical Chemistry and Transfusion Medicine, The Sahlgrenska Academy, University of Gothenburg, Sweden
    Biochem Biophys Res Commun 412:494-9. 2011
    ..In untreated acute phase LNB patients, 67% showed a significant increase of CSF α-DG-N compared to healthy controls. After treatment with antibiotics the CSF α-DG-N levels were normalized in the LNB patients...
  75. ncbi Synaptic retrogenesis and amyloid-beta in Alzheimer's disease
    Pontus Wasling
    Department of Physiology, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
    J Alzheimers Dis 16:1-14. 2009
    ..Here, we review the literature on the possible physiological roles of Abeta and its precursor protein AbetaPP during development with special focus on electrophysiological findings...
  76. ncbi Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Sahlgren s University Hospital Mölndal, S 431 80 Molndal, Sweden
    Mol Med Report 1:757-61. 2008
    ..Taken together, these data suggest that differentially-expressed peptides are general markers of axonal degeneration. Further studies are needed to verify their prognostic value in FTD...
  77. ncbi No neurochemical evidence for brain injury caused by heading in soccer
    Henrik Zetterberg
    Institute of Neuroscience and Physiology, Department of Neurochemistry and Psychiatry, The Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    Br J Sports Med 41:574-7. 2007
    ..The possible injurious effect to the brain of heading in soccer is a matter of discussion...
  78. ncbi Cerebrospinal fluid markers for prediction of Alzheimer's disease
    Henrik Zetterberg
    Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Goteborg University, S 413 45 Gothenburg, Sweden
    Neurosci Lett 352:67-9. 2003
    ..The usefulness of these markers is further emphasized by the finding of a positive predictive value of 94% and a negative predictive value of 81%...
  79. ncbi Cerebrospinal fluid biomarkers for Alzheimer's disease
    Kaj Blennow
    Clinical Neurochemistry Laboratory, The Sahlgrenska Academy at Goteborg University, Molndal, Sweden
    J Alzheimers Dis 18:413-7. 2009
    ..This paper reviews recent research advances on these CSF biomarkers for use in clinical diagnosis and in clinical trials in AD...
  80. ncbi Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease
    Henrik Zetterberg
    Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Goteborg University, S 413 45 Gothenburg, Sweden
    Neurosci Lett 367:194-6. 2004
    ..35; P = 0.020), although this correlation failed to reach significance in the AD group alone (r = -0.38; P = 0.099). Taken together, the data indicate that TGF-beta1 plays a role in the processes that affect amyloid metabolism in AD...
  81. ncbi Expression of the gene encoding the ghrelin receptor in rats selected for differential alcohol preference
    Sara Landgren
    Department of Pharmacology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, SE 405 30 Gothenburg, Sweden
    Behav Brain Res 221:182-8. 2011
    ..Therefore the GHS-R1A may constitute a novel candidate for development of new treatment strategies for alcohol dependence...
  82. ncbi Methylenetetrahydrofolate reductase genetic polymorphisms in patients with cataract
    Madeleine Zetterberg
    Institute of Clinical Neuroscience, Section of Ophthalmology, Sahlgrenska University Hospital, Goteborg University, Molndal, Sweden
    Am J Ophthalmol 140:932-4. 2005
    ..The level of homocysteine can be lowered by dietary intake of folate. A protective effect of folate supplementation has been reported against cataract. Here we investigate MTHFR polymorphisms in human cataract...
  83. ncbi Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease
    Annica Johansson
    Department of Clinical Neuroscience, Sahlgrenska University Hospital, Goteborg University, Goteborg, Sweden
    Hum Genet 114:581-7. 2004
    ..Our results provide an important independent replication of previous findings, supporting the existence of CYP46A1 sequence variants that contribute to variability in beta-amyloid metabolism...
  84. ncbi Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall
    Niklas Mattsson
    Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Institute of Neuroscience and Physiology, Göteborg and Mölndal, Sweden
    Clin Chem Lab Med 48:603-7. 2010
    ..Here, we discuss the causes of these variations, and present a global quality control program to overcome them...
  85. ncbi Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease
    Malin von Otter
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Bla Straket 15, 413 45 Gothenburg, Sweden
    BMC Med Genet 11:36. 2010
    ..Here, we hypothesize that variation in NFE2L2 and KEAP1, the genes encoding the two major regulators of the phase II response, may affect the risk of Parkinson's disease...
  86. ncbi Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF
    Ulla Ruetschi
    Institute of Laboratory Medicine, Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Goteborg University, Sweden
    Exp Neurol 196:273-81. 2005
    ..With use of these potential biomarkers, FTD can be distinguished from control subjects with high accuracy in this pilot study...
  87. ncbi Targeted proteomics in Alzheimer's disease: focus on amyloid-beta
    Erik Portelius
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at Goteborg University, Molndal, Sweden
    Expert Rev Proteomics 5:225-37. 2008
    ..From a longer perspective, establishment of the most effective combinations of different biomarkers and other diagnostic modalities may be foreseen...
  88. ncbi Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, Sahlgren s University Hospital, S 431 80 Molndal, Sweden
    Neurosci Lett 414:233-6. 2007
    ..360, p=0.012). These results suggest that siblings of MS patients have an increased oxidative stress response to environmental and/or genetic factors that may be involved in MS pathogenesis...
  89. ncbi Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years
    Henrik Zetterberg
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at Goteborg University, Molndal, Sweden
    J Alzheimers Dis 12:255-60. 2007
    ..Thus, even minor biochemical changes induced by treatment against AD should be detectable using these biomarkers, which bodes well for their usefulness as surrogate markers for drug efficacy in clinical trials...
  90. ncbi No association between the MTHFR A1298C and transcobalamin C776G genetic polymorphisms and hyperhomocysteinemia in thrombotic disease
    Henrik Zetterberg
    Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, , Sweden
    Thromb Res 108:127-31. 2002
  91. ncbi Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
    Kaj Blennow
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, SE 431 80 Molndal, Sweden
    Nat Rev Neurol 6:131-44. 2010
    ..Furthermore, we outline the roles of CSF biomarkers in drug discovery and clinical trials, and provide perspectives on AD biomarker discovery and the validation of such markers for use in the clinic...
  92. ncbi Influence of the apolipoprotein E epsilon4 allele on human embryonic development
    Henrik Zetterberg
    Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Goteborg University, 41345 Gothenburg, Sweden
    Neurosci Lett 324:189-92. 2002
    ..005), suggesting that epsilon4 may have protective effects during embryogenesis. These protective effects might counterbalance the deleterious age-related effects of the epsilon4 allele in natural selection...
  93. ncbi Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
    Magnus Gisslen
    Department of Infectious Diseases, University of Gothenburg, Sahlgrenska University Hospital, SE 416 85 Gothenburg, Sweden
    BMC Neurol 9:63. 2009
    ..Because of the emerging intersections of HIV infection and Alzheimer's disease, we examined cerebrospinal fluid (CSF) biomarkers related of amyloid and tau metabolism in HIV-infected patients...
  94. ncbi Monitoring of brain interstitial total tau and beta amyloid proteins by microdialysis in patients with traumatic brain injury
    Niklas Marklund
    Department of Neuroscience, Neurosurgery, Uppsala University Hospital, Uppsala, Gothenburg, Sweden
    J Neurosurg 110:1227-37. 2009
    ....
  95. ncbi Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos
    Henrik Zetterberg
    Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Goteborg University, Sweden
    Eur J Hum Genet 10:113-8. 2002
    ..The present finding of high prevalence of mutated MTHFR genotypes in spontaneously aborted embryos emphasises the potential protective role of periconceptional folic acid supplementation...
  96. ncbi Gene-gene interaction between fetal MTHFR 677C>T and transcobalamin 776C>G polymorphisms in human spontaneous abortion
    Henrik Zetterberg
    Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Goteborg University, S 413 45 Goteborg, Sweden
    Hum Reprod 18:1948-50. 2003
    ..It was hypothesized that there may be a significant interaction between MTHFR and TC genotypes which affects the pathogenesis of spontaneous abortion...
  97. ncbi Cystatin C in cerebrospinal fluid and multiple sclerosis
    Sara F Hansson
    Department of Clinical Neuroscience, University of Goteborg, Sahlgrenska University Hospital Molndal, Molndal, Sweden
    Ann Neurol 62:193-6; discussion 205. 2007
    ..A recent study using surface-enhanced laser desorption/ionization time-of-flight analysis of cerebrospinal fluid identified a 12.5 kDa truncated isoform of cystatin C (CysC) as a specific biomarker for multiple sclerosis (MS)...
  98. ncbi Association of APOE with age at onset of sporadic amyotrophic lateral sclerosis
    Henrik Zetterberg
    Department of Neurochemistry and Psychiatry, Sahlgrenska University Hospital, Goteborg University, Sweden
    J Neurol Sci 273:67-9. 2008
    ..027). These data support APOE epsilon4 as a subordinate contributing factor in ALS...
  99. ncbi Dopamine D2 receptor genotype is associated with increased mortality at a 10-year follow-up of alcohol-dependent individuals
    Ulf Berggren
    Institute of Clinical Neuroscience, Section of Psychiatry, Sahlgrenska Academy at Goteborg University, SE 405 30 Goteborg, Sweden
    Alcohol Alcohol 45:1-5. 2010
    ....
  100. ncbi B-type natriuretic peptide plasma levels are elevated in subcortical vascular dementia
    Daniel Kondziella
    Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden
    Neuroreport 20:825-7. 2009
    ..This probably reflects the larger cardiovascular burden in patients with subcortical vascular dementia...
  101. ncbi The transcobalamin (TC) codon 259 genetic polymorphism influences holo-TC concentration in cerebrospinal fluid from patients with Alzheimer disease
    Henrik Zetterberg
    Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, , S-413 45 Gothenburg, Sweden
    Clin Chem 49:1195-8. 2003